fbpx

My Biggest Takeaway from the 2018 Cholesterol Guidelines

In late 2018, ACC and AHA came out with an update to their cholesterol guidelines. The last update was from 2013 so PCSK-9 inhibitors hadn’t even been approved at that time.

Very High Risk Patients – My Biggest Takeaway

I always had a hard time knowing when to recommend further lipid lowering therapy to a patient who has been maximized on their statin. In 2016, ezetimibe was studied and shown to improve cardiovascular outcomes in selected patients. Prior to this, we only knew that ezetimibe reduced LDL, but it was not known whether that would impact outcomes.

What is a very high-risk patient? This type of patient is a secondary prevention patient (i.e. already had a heart attack) who remains with risk factors. This is usually one of those patients where you know it when you see them. The patient who has had numerous heart attacks, still smokes, has diabetes, has had a heart attack while on high dose statin, or has CKD would be classified as high risk. You can find a full list of criteria here.

The goals are back. In this type of very high risk patient, I previously really struggled knowing what to do as the 2013 guidelines did not give much guidance. Now, in this type of patient, the LDL goal is going to be 70. We like goals and it is easy to go by the numbers.

Let’s take an example. We have a 63 year old who has had 3 heart attacks, is on maximally tolerated statin (atorvastatin 80) and has type 2 diabetes. This patient easily fits into the very high risk criteria. His current LDL is 98. with a goal of less than 70. Ezetimibe (along with continued diet/lifestyle coaching) is where I would prefer to start with this patient.

Some may make the argument that ezetimibe will not lower LDL that much and while that is a valid argument, I would want to see what we could do with adding that agent prior to a PCSK9 inhibitor. This is due to the significant expense of the PCSK9 inhibitors. There was a recent price reduction reported, but the cost is still very high. Ezetimibe will be much cheaper, but will likely not reduce LDL as much as a PCSK9 inhibitor. This brings up a huge opportunity to talk to our patients and help them work through the risks, costs, and potential benefits of each agent.

Adherence deserves an additional mention. Statin adherence rates are abysmal. When you have a patient presenting with elevated cholesterol who is on a statin (listen to the podcast), you have to remember to monitor and assess for adherence issues. I’ve had patients skip doses, take half-doses, or simply forget to take their statin for various reasons. Here are a few more pearls on patient adherence you need to remember.

The guidelines do allow for triple therapy (ezetimibe, statin, PCSK9 inhibitor) for those very high-risk patients who are not getting to the goal of <70. That will be a consideration in some patients that we have a hard time getting down that LDL.

Over 6,000 healthcare professionals have subscribed for our FREE Giveaways. Why haven’t you?!

Study Materials For Pharmacists and Students – Amazon Books

Useful Books For Any Healthcare Professional

Nursing Professionals and Students

Dietitian Professionals

Written By Eric Christianson

January 23, 2019

Free PDF – Top 30 Medication Mistakes

Enjoy the blog?  Over 6,000 healthcare professionals follow the blog, why aren't you? Subscribe now and get a free gift as well!

Explore Categories